A peptide nucleic acid (PNA) bridge allows cell-penetrating peptides to deliver functional cargo without interfering with its activity inside cells.
8-mer PNA bridgeenabled intracellular release of functional cargo without CPP charge interference
What the researchers found
The core problem: cell-penetrating peptides (CPPs) have positive charges that can interfere with the function of attached cargo peptides inside cells. Direct conjugation often does not work reliably.
The solution: an 8-unit PNA sequence conjugated to octa-arginine CPP (PNA1-CPP) paired with a complementary PNA attached to an autophagy-inducing peptide (PNA2-AIP). The two PNA strands hybridized, forming a stable 1:1 complex that kept the functional peptide connected to the CPP during delivery.
Once inside cells, at least some of the PNA1-CPP/PNA2-AIP complexes dissociated, releasing the functional AIP from the positively charged CPP. The released PNA2-AIP induced significantly more autophagy than AIP directly conjugated to CPP (CPP-AIP). The PNA hybrid system also caused minimal cell death.
Why it matters
Getting therapeutic peptides inside cells is one of the biggest challenges in peptide drug development. This PNA-based system solves a specific problem: CPP charges interfering with cargo function. By acting as releasable molecular glue, PNAs could become a general platform for intracellular peptide delivery.
The numbers in context
8-mer PNA bridge; 1:1 hybrid; improved autophagy vs direct conjugation; minimal cytotoxicity
How the study worked
In vitro cell culture study. Researchers synthesized PNA-peptide conjugates using solid-phase peptide synthesis, confirmed 1:1 hybrid formation, measured cellular uptake, tracked intracellular dissociation, quantified autophagy induction (compared to direct CPP-AIP conjugate), and assessed cell viability.
Who was studied
Cell culture (single cell type)
What this study cannot tell us
Tested in one cell type with one cargo peptide (autophagy inducer). The generalizability to other functional peptides and cell types is unknown. The extent of intracellular PNA dissociation ("at least some portion") was not fully quantified. No in vivo testing. PNA synthesis adds cost and complexity to the system.
How to read the evidence
Preliminary evidence. Proof-of-concept demonstrated with one cargo peptide in one cell type.
When this study was published
Published in 2020. PNA-based delivery continues to be explored as a platform technology.
The bigger picture
Getting therapeutic peptides inside cells is one of the biggest challenges in drug development. This PNA bridge technology solves a specific and common problem — CPP interference — that has stalled many peptide drug candidates.
Questions still open
- Does this approach work with different cargo peptides beyond autophagy inducers?
- How quickly does the PNA bridge release its cargo once inside cells?
- Can this system be scaled for pharmaceutical manufacturing?
Common questions
Why do cell-penetrating peptides interfere with their cargo?
How does the PNA bridge solve this?
Read the original research
Intracellular delivery of a peptide nucleic acid-based hybrid of an autophagy inducing peptide with a cell-penetrating peptide.
Organic & biomolecular chemistry, 18(10), 1978-1986
Citation
Hakata, Yoshiyuki; Ishikawa, Suzuka; Ohtsuki, Takashi; Miyazawa, Masaaki; Kitamatsu, Mizuki. (2020). Intracellular delivery of a peptide nucleic acid-based hybrid of an autophagy inducing peptide with a cell-penetrating peptide.. Organic & biomolecular chemistry, 18(10), 1978-1986. https://doi.org/10.1039/c9ob02559f